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Background. Intraglomerular lipid deposition is frequently ob-
served in routine renal biopsies, and it has been suggested that
lipid peroxidation of low density lipoprotein (LDL) may be
implicated in the pathogenesis of progressive glomerulosclerosis.
We have examined whether oxidized LDL (Ox-LDL) is present in
the glomeruli of patients with renal disease and whether intrinsic
human glomerular cells express NADPH-oxidase (a superoxide-
generating enzyme found in professional phagocytes).
Methods. Immunocytochemical study was performed on 939
renal biopsy specimens, using monoclonal antibodies (mAbs)
OL-10, 48 and 449, and polyclonal antiobody against human
apolipoprotein (apo) B. Mouse mAb OL-10 recognizes malondi-
aldehyde (MDA)-modified peptide epitope, and mAbs 48 and 449
react with a and b subunits of cytochrome b558, an essential
component of NADPH-oxidase.
Results. Sixty-two (6.6%) of the 939 patients with renal disease
exhibited a staining for MDA-altered protein or Ox-LDL in the
glomeruli, mainly in the sclerotic segments or mesangial areas.
Group 1 patients with heavy Ox-LDL deposition mainly in the
sclerotic segments showed a higher frequency of renal insuffi-
ciency and heavy proteinuria and a greater degree of glomerulo-
sclerosis, compared to those in group 2 with mesangial Ox-LDL
staining. The distribution of MDA protein epitopes, in general,
paralleled the deposition of apo B epitopes. Immunoelectron
microscopy of ultrathin frozen sections showed the presence of
immunogold particles for mAbs 48 and 449 in the cytoplasm of
resident glomerular cells of both normal and diseased kidneys.
When immunoblotted with mAb OL-10, one band from the IgA
nephropathy and focal segmental glomerulosclerosis groups at
;260 kD was labeled, whereas immunostaining of normal control
samples revealed no staining.
Conclusions. These results indicate that Ox-LDL is present
mainly in the lesions of glomerulosclerosis and mesangial areas in
human renal biopsies. They also suggest that patients with heavy
Ox-LDL accumulation in the sclerotic segments of glomeruli have
more advanced renal disease than those with mesangial Ox-LDL
and that resident glomerular cells generate cytochrome b558, the
potential of which may not suffice to induce peroxidation of LDL
in the diseased glomeruli.
Superoxide (O2
2) or other reactive oxygen species
(ROS) are known to be involved in the mediation of renal
injury [1, 2]. ROS cause lipid peroxidation of low density
lipoprotein (LDL), which results in derivatization of lysine
residues of apolipoprotein (apo) B by lipid peroxide break-
down products, such as malondialdehyde (MDA) and
4-hydroxynonenal [3]. Studies have suggested that oxidized
LDL (Ox-LDL) may be implicated in the pathogenesis of
progressive glomerulosclerosis [4–8]. In support of this
view, the presence of Ox-LDL has been demonstrated in
the glomeruli of rats with focal segmental glomeruloscle-
rosis (FSGS) [9, 10]. Furthermore, dietary antioxidant
reduced not only the staining intensity of Ox-LDL but also
the severity of renal injury in this animal model [10].
In a previous study, we reported that apo B-containing
lipoproteins were frequently accumulated in the glomeruli
of patients with various glomerular diseases [11]. It is
conceivable that locally accumulated apo B-containing
lipoproteins in the glomeruli provide polyunsaturated fatty
acids as substrates for lipid peroxidation. To date, however,
Ox-LDL has not been immunohistochemically demon-
strated in the glomeruli of renal patients [12]. Only weakly
immunoreactive hypochlorite (HOCl)-modified proteins
have been demonstrated in the glomeruli of patients with
nephrosclerosis, but not in those with minimal lesion or
FSGS [13].
The source of ROS in the glomeruli of renal patients is
unclear. NADPH-oxidase complex is the most familiar
source of superoxide generated for bacterial killing in
neutrophils [14, 15]. The same oxidase is believed to be
present in all the professional phagocytes, including mono-
cytes/macrophages [16]. This enzyme complex catalyzes the
transfer of electrons from NADPH via cytochrome b558 to
oxygen [14–16]. Radeke et al first demonstrated that
cultured human mesangial cells, nonphagocytes, express
the NADPH-oxidase complex [17]. In addition, glomerular
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epithelial cells and mesangial cells of rats with passive
Heymann nephritis (PHN) were found to express cyto-
chrome b558 [18]. No study, however, has identified the
NADPH-oxidase system in human glomeruli in situ.
The present study was designed to determine whether
Ox-LDL is present in human renal biopsies and whether
intrinsic glomerular cells express the ROS-generating sys-
tem. We demonstrated that MDA-altered protein, which
co-localized with apo B-containing lipoprotein, occurred
mainly in the FSGS lesions and mesangial areas of patients
with renal disease and that resident glomerular cells gen-
erated cytochrome b558.
METHODS
Antibodies
Mouse monoclonal antibody, mAb OL-10, was raised
against human Cu11-catalyzed Ox-LDL and was specific
for the MDA-modified peptide epitope, as we have previ-
ously described [7]. Mouse mAb 449, which reacted with
the low molecular weight a-subunit of 22 to 23 kD, and
mAb 48, which reacted with the high molecular weight
b-subunit of 75 to 90 kD of purified neutrophil cytochrome
b558 [19], were kindly donated by Dr. Dirk Roos, Central
Laboratory of the Netherlands Red Cross Blood Transfu-
sion Service. Goat anti-apo B and rhodamine-conjugated
rabbit anti-goat IgG were supplied by Chemicon (Te-
mecula, CA, USA); mouse anti-human CD68, FITC-la-
beled rabbit anti-mouse immunoglobulin, and horseradish
peroxidase-conjugated goat anti-mouse immunoglobulin
were purchased from Dakopatts (Glostrup, Denmark), and
FITC-labeled rabbit anti-goat IgG from Kallestad (Austin,
TX, USA). Affinity-purified goat anti-mouse IgG-10 nm-
gold was obtained from Amersham (Arlington Heights, IL,
USA).
Pathological study
A total of 939 renal biopsies having more than ten
glomeruli were subjected to light, electron, and immuno-
fluorescence microscopy using standard methodologies. By
light microscopy, segmental sclerosis was defined as seg-
mental collapse and solidification of glomeruli associated
with excess mesangial matrix accumulation. Global sclero-
sis was defined as total collapse with solidification involving
the whole glomerulus. The term “glomerulosclerosis” was
used to describe both segmental sclerosis and global scle-
rosis, as described [20].
Normal control specimens were obtained from com-
pletely normal regions of four nephrectomy specimens that
elsewhere contained renal cell carcinoma, and from four
renal biopsy specimens at the time of donation for kidney
transplantation.
Immunofluorescence microscopy
Biopsy specimens were embedded in Tissue-Tek O.C.T.
compound, immersed in cooled isopentane, and snap fro-
zen in liquid nitrogen. Cryostat sections were fixed for 10
minutes in freshly prepared 4% paraformaldehyde, 20 mM
butylated hydroxytoluene (BHT), 2 mM EDTA, and 5%
sucrose. These were rinsed three times for five minutes in
0.1 M phosphate buffered solution (PBS), pH 7.4, contain-
ing 20 mM BHT, 2 mM EDTA, and 5% sucrose. To detect
MDA-altered protein, human macrophage CD68, or cyto-
chrome b558, sections were incubated with either mAb
OL-10 (2 mg/ml), anti-CD68 (1:50), mAb 449 (2.5 mg/ml) or
mAb 48 (2.5 mg/ml) for one hour at 25°C, followed by
FITC-labeled rabbit anti-mouse immunoglobulin (1:50).
The staining method used to detect apo B epitopes has
been previously described [11]. Positive tissue control for
MDA-altered protein or Ox-LDL was obtained from aorta
sections containing fibro-fatty atherosclerotic lesions at the
time of autopsy. Negative control studies were performed
by omitting the primary antibodies or replacing them with
corresponding non-immune serum. Sections were mounted
in 1% p-phenylene-diamine-glycerol, pH 8.0, and examined
with a Zeiss fluorescence microscope.
For double immunostaining, two primary antibodies,
mAb OL-10 and goat anti-apo B (1:220), were used. After
reaction with primary antibodies, the sections were exposed
to two secondary antisera, FITC-labeled rabbit anti-mouse
immunoglobulin and rhodamine-conjugated rabbit anti-
goat IgG (1:200).
Specificity for the staining of MDA-modified proteins
was further confirmed by absorption test and summarized
below: mAb OL-10 with a staining titer of 1:2 was diluted
twofold in buffer and mixed with an equal volume of 500
mg/ml Cu11-catalyzed-Ox-LDL or MDA-altered LDL.
Cu11-catalyzed Ox-LDL and MDA-altered LDL were
prepared, as we have previously described [7]. After incu-
bation at 37°C for one hour, the mixture was centrifuged at
4°C, at 9,000 rpm for 30 minutes, and the supernatant was
tested for the ability to stain MDA-altered proteins.
Immunogold electron microscopy
Small (1 mm3) pieces of the renal biopsy were immersed
in 2% paraformaldehyde and 0.2% glutaraldehyde for two
hours at 4°C, washed twice for five minutes at 4°C with 0.1
M PBS, infiltrated with 2.3 M sucrose for more than one
hour and frozen in liquid nitrogen. Ultrathin frozen sec-
tions were prepared using a Reichert FCS low-temperature
sectioning system, and these were mounted on Formvar-
coated 100-mesh nickel grids. These were incubated over-
night with either mAb 449 (0.6 mg/ml) or mAb 48 (0.6
mg/ml). Excess unbound primary antibody was washed off
the grids using PBS containing 1% bovine serum albumin
and 0.05% Tween-20, as we have previously described [21].
The grids were then exposed to 10 nm gold-labeled goat
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anti-mouse IgG (1:30) for two hours at room temperature,
and washed first with PBS and then with distilled water.
Afterwards, the sections were stained for 10 minutes with
uranyl acetate and for five minutes with lead citrate, and
observed with a Hitachi 7100 electron microscope. For
negative controls, the primary antibody was omitted or
replaced by corresponding non-immune serum.
Protein electrophoresis and Western blots
We chose the groups of IgA nephropathy and FSGS with
sufficient amounts of frozen tissue for Western blot analysis
of MDA-altered protein. Frozen renal biopsy specimens
from two disease groups were pooled in buffer A contain-
ing 0.15 M NaCl and 0.24 mM EDTA, pH 7.4, sonicated and
dissolved in 0.2 N NaOH. Samples and Cu11-catalyzed
Ox-LDL were electrophoretically resolved in 5% polyacryl-
amide gel in sodium dodecyl sulfate (SDS) buffer under
reducing conditions and transferred onto nitrocellulose
membrane. The blots were incubated in blocking solution
for one hour and incubated with mAb OL-10 at room
temperature for one hour. For competition experiments,
mAb OL-10 preabsorbed with excess Cu11-catalyzed Ox-
LDL was used. Bound murine antibody was visualized by
the subsequent incubation with horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin and enhanced
chemiluminescence detection kit (Amersham).
Statistics
The significance of differences between groups was ob-
tained using a two-tailed Student’s t-test and the Chi-
square test. All differences were considered significant for
P , 0.05. Results were expressed as means 6 SD.
RESULTS
Characteristics of patients
Of the 939 biopsies, 62 (6.6%) showed positive staining
for Ox-LDL in the glomeruli. Patients were grouped ac-
cording to pathologic diagnosis in Table 1, in which the
frequency of Ox-LDL deposition is shown. The diagnoses
included idiopathic FSGS (14%), post-transplantation
FSGS (43%), IgA nephropathy (5%), membranoprolifera-
tive glomerulonephritis (10%), crescentic glomerulone-
phritis (29%), diabetes mellitus (13%), hypertensive ne-
phropathy (27%), and end-stage renal disease (33%).
The 62 patients with positive staining for Ox-LDL were
also grouped according to its intraglomerular localization:
group I had Ox-LDL deposition in the sclerotic segments,
crescents or subendothelial areas, and totaled 27 patients
(44%); group 2’s staining was mainly in the mesangial
areas, and totaled 35 patients (56%). Clinical data of group
1 at the time of biopsy are summarized in Table 2.
Hypercholesterolemia, defined as a cholesterol level
greater than 240 mg/dl, was observed in 10 patients (37%).
Renal insufficiency, diagnosed as serum creatinine greater
than 1.5 mg/dl or as creatinine clearance lower than 80
ml/min/1.73 m2, was noted in 20 patients (74%). Protein-
uria was present in all with the amounts excreted ranging
from 0.4 to 8 g per day; in 16 patients (59%), the amount
was $3.5 g per day. All patients in group 1 showed
glomerulosclerosis affecting 12% to 92% (mean 58% 6
31%) of the glomeruli (Table 2).
Clinical data of group 2 are summarized in Table 3.
Hypercholesterolemia was present in 11 patients (31%),
and renal insufficiency in 17 (49%). Proteinuria was ob-
served in 33 patients with the amounts excreted ranging
from 0.3 to 14 g per day; in 10 (29%), the amount was
$3.5 g per day. Twenty-two cases exhibited glomeruloscle-
rosis affecting 1% to 86% (mean 18% 6 18%) of the
glomeruli (Table 3).
In group 1, the frequency of renal insufficiency and heavy
proteinuria, as well as the percentage of glomeruli with
glomerulosclerosis were significantly higher as compared
with those in group 2 (P , 0.05 or P , 0.01).
Localization of MDA-altered proteins and apo B in
human glomeruli
Sixty-two (6.6%) of the 939 renal biopsies exhibited
staining for MDA-altered protein or Ox-LDL in the glo-
meruli by indirect immunofluorescence. Twenty-two of
them showed localized but heavy accumulation of Ox-LDL
in the sclerotic segments of glomeruli (Fig. 1 A, B), where
staining for apo B epitopes was also present. Four patients
diagnosed with either crescentic glomerulonephritis, sys-
temic lupus erythematosus, or Henoch-Scho¨nlein nephritis
exhibited localization of Ox-LDL in crescents. In a case
with membranoproliferative glomerulonephrtis, clumpy
Table 1. Frequency of intraglomerular oxidized low density lipoprotein
deposition in renal biopsies
Diagnosis
No.
examined
No. of
positive cases
(%)
Minimal lesion 131 3 (2.3)
FSGS 85 12 (14.1)
FSGS, recurrent 7 3 (42.9)
IgA nephropathy 272 14 (5.1)
Acute postinfectious GN 39 1 (2.6)
Membranous nephropathy 77 1 (1.3)
Membranoproliferative GN 40 4 (10.0)
Mesangial proliferative GN, nonspecific 55 2 (3.6)
Diffuse crescentic GN 7 2 (28.6)
Systemic lupus erythematosus 75 7 (9.3)
Diabetes mellitus 16 2 (12.5)
Henoch-Scho¨nlein nephritis 25 2 (8.0)
Tubulointerstitial disease 23 1 (4.3)
Hypertensive nephropathy 15 4 (26.7)
Transplant nephropathy 42 2 (4.8)
End-stage renal disease 6 2 (33.3)
Miscellaneous 24 0
Total 939 62 (6.6)
Abbreviations are: FSGS, focal segmental glomerulosclerosis; GN,
glomerulonephritis; No., number.
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deposition of Ox-LDL occurred in subendothelial areas
(Fig. 1C). In the remaining 35 patients, intracellular and/or
extracellular deposition of Ox-LDL was present mainly in
mesangial areas (Fig. 1D). Surprisingly, six (75%) of the
eight normal controls and many biopsy samples showed
weak staining for the MDA-specific epitope in the periph-
ery of the glomerular capillary loops (Fig. 1E). In this area,
however, staining for apo B epitopes was negative. The
specificity of staining for MDA-altered protein was con-
firmed by an absorption test (Fig. 1F).
Dual immunofluorescence of the same section of kidney,
using mAb OL-10 and anti-apo B, demonstrated co-local-
ization of reactive epitopes in the mesangial areas or
sclerotic segments of glomeruli (Fig. 2 A–C).
Also, 85 (9.1%) of the 939 renal biopsies showed local-
ization of MDA-altered protein in intimal or subendothe-
lial layer and media of interlobular arteries (Fig. 3).
All three patients with post-transplantation recurrent
FSGS and intraglomerular Ox-LDL deposition had more
than one post-transplantation renal biopsy. In first or
previous biopsy samples, showing a lower percentage of the
glomeruli with sclerosis compared to the current ones, no
staining for Ox-LDL was demonstrable.
Localization of cytochrome b558 in human glomeruli
Indirect immunofluorescence study was performed using
mAbs 48 and 449 on 174 biopsies. Forty-five cases (25.9%)
showed positive staining mainly in cells in the mesangium.
In the glomeruli of patients with IgA nephropathy or
postinfectious glomerulonephritis, they showed a segmen-
tally distributed, punctate, cytoplasmic pattern (Fig. 4).
These cells frequently matched for CD68-positive cells. In
some cases with membranous nephropathy and minimal
lesion, which showed no infiltration of neutrophils or
monocytes, patchy cytoplasmic staining for mAbs 48 and
449 was rarely seen in glomerular epithelial cells and in
mesangial cells.
Table 2. Characteristics of patients with oxidized low density lipoprotein in sclerotic lesions or crescents of glomeruli
Diagnosis N
Sex
(M:F)
Age
years
Cholesterol
mg/dl
CCr
ml/min/1.73m2
Proteinuria
g/day
Glomerulosclerosis
%
FSGS 6 2:4 32 6 13 251 6 86 57 6 28 4.9 6 2.0 61 6 35
FSGS, recurrent 2 1:1 13, 18 432, 339 31, 38 4.0, 3.9 75, 55
IgA nephropathy 7 4:3 34 6 22 229 6 84 62 6 57 2.5 6 1.7 47 6 35
Membranoproliferative GN 2 1:1 17, 49 120, 317 37, 120 1.1, 3.6 12, 50
Crescentic GN 2 2:0 74, 53 183, 177 18, 31 1.6, 2.3 68a, 82a
HSN 1 0:1 8 249 80 2 22
SLE 3 0:3 26 6 4 354 6 148 26 6 20 6.4 6 0.8 86 6 5
Diabetes mellitus 2 2:0 52, 67 206, 167 54, 52 5.8, 0.8 58, 20
End-stage renal disease 2 2:0 24, 28 198, 153 9, 29 7.2, 1.3 91, 79
Total 27 14:13 34 6 19 251 6 103 49 6 37 3.7 6 2.2 58 6 31
Abbreviations are: CCr, creatinine clearance; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HSN, Henoch-Scho¨nlein nephritis;
SLE, systemic lupus erythematosus. Values are mean 6 SD.
a Including % of glomeruli with crescents
Table 3. Characteristics of patients with oxidized low density lipoprotein in mesangial areas of glomeruli
Diagnosis N
Sex
(M:F)
Age
years
Cholesterol
mg/dl
CCr
ml/min/1.73/m2
Proteinuria
g/day
Glomerulosclerosis
%
Minimal lesion 3 3:0 23 6 9 475 6 43 83 6 27 7.8 6 4.8 1 6 2
FSGS 6 5:1 31 6 24 195 6 43 82 6 49 2.1 6 1.3 25 6 17
FSGS, recurrent 1 0:1 58 478 43 14.0 86
IgA nephropathy 7 5:2 27 6 12 181 6 56 86 6 30 1.8 6 1.1 27 6 11
Acute postinfectious GN 1 0:1 22 248 30 6.9 20
Membranous nephropathy 1 1:0 42 246 82 3.8 7
Membranoproliferative GN 2 2:0 17, 48 271, 319 29, 77 1.2, 8.5 5, 4
Mesangial proliferative GN, nonspecific 2 1:1 16, 58 139, 163 141, 67 1.2, 0.5 0, 2
Systemic lupus erythematosus 4 0:4 35 6 3 206 6 52 82 6 20 3.0 6 1.8 15 6 12
Henoch-Scho¨nlein nephritis 1 1:0 9 186 101 0.7 0
Tubulointerstitial disease 1 0:1 43 176 76 0 0
Hypertensive nephropathy 4 3:1 48 6 13 200 6 33 72 6 30 1.3 6 1.1 18 6 10
Transplant nephropathy 2 2:0 39, 30 233, 215 45, 56 0, 0.9 0.2, 0
Total 35 23:12 32 6 16 235 6 110 78 6 31 3.2 6 3.4 18 6 18
Values are mean 6 SD. Abbreviations are in Table 2.
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By immunoelectron microscopy of ultrathin frozen sec-
tions, binding of mAbs 48 and 449 was noted in the
cytoplasm of intrinsic glomerular cells of both normal
controls and patients with renal disease (Fig. 5). Particle
labeling against cytochrome b558 was scattered in the
cytoplasm; it was not specifically localized in intracellular
vesicles. There was no labeling for cytochrome b558 within
the immune deposits. As expected, more gold particle
Fig. 1. Localization of malondialdehyde (MDA) protein epitopes by immunofluorescence in glomeruli of patients with focal segmental glomerulo-
sclerosis (FSGS) (A, D), diabetes mellitus (B), and membranoproliferative glomerulonephritis (C), and of a normal control (E). Localized heavy
staining for MDA-altered protein is shown in the sclerotic segments (A, B), subendothelial areas (C), or mesangial areas (D) of glomeruli. In contrast,
only specks for MDA protein epitopes are noted in the periphery of glomerular capillary loops of a normal control (E). A parallel section to that shown
in (A), showing no staining for MDA epitopes when mAb OL-10 was preabsorbed with excess MDA-altered LDL (F). Original magnification, 3400.
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density for cytochrome b558 was found within polymorpho-
nuclear leukocytes present in capillary lumen than within
glomerular cells.
Western blot analysis of MDA-altered protein in renal
biopsies
Pooled renal biopsy samples from IgA nephropathy and
FSGS groups, normal control samples and Cu11-catalyzed
Ox-LDL were dissolved in SDS-sample buffer, and 22 mg or
38 mg of protein from each preparation was subjected to
SDS-gel electrophoresis and immunoblotting. When immu-
noblotted with mAb OL-10, one band from the two disease
groups at ;260 kD was labeled, whereas immunostaining
of normal control samples revealed no staining. Immuno-
blotting of Ox-LDL with mAb OL-10 showed that two
proteins of approximate molecular weight ;240 kD and
;260 kD were immunoreactive (Fig. 6). Competition ex-
periments with mAb OL-10 preabsorbed with Ox-LDL
Fig. 2. Dual immunofluorescence of glomeruli from patients with focal
segmental glomerulosclerosis (FSGS) (A, C), and IgA nephropathy (B).
The same glomerular sections were stained with mAb OL-10 (FITC) and
anti-apolipoprotein (apo) B (rhodamine). When both fluorochromes are
viewed simultaneously, co-localization of MDA-altered protein and apo
B-containing lipoprotein can be appreciated in mesangial areas (A), and
in the lesions of glomerulosclerosis (B,C). Original magnification, 3400.
Reproduction of this figure in color was made possible by a grant from
Cheil Jedang Corporation, Seoul, Korea.
Fig. 3. Localization of malondialdehyde (MDA)-altered protein by im-
munofluorescence in intimal or subendothelial layer and media of a
preglomerular artery. Original magnification, 3400.
Fig. 4. Localization of cytochrome b558 by immunofluorescence in a
glomerulus of a patient with IgA nephropathy. Segmental cytoplasmic
staining for cytochrome b558 is seen in mesangial area. Original magnifi-
cation, 3400.
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prevented antibody binding, indicating that staining was
specific for MDA-modified protein.
DISCUSSION
The main finding of this study is that Ox-LDL is present
in human renal biopsies. We demonstrated by immunoflu-
orescence the presence of MDA-altered protein, which
co-localized with apo B-containing lipoprotein, mainly in
the lesions of FSGS and mesangial areas.
The occurrence of MDA-modified protein within the
lesions of FSGS is similar to that described within ather-
oma of Watanabe heritable hyperlipidemic rabbits [22–24]
and supports the hypothesis that glomerulosclerosis is
analogous to atherosclerosis [4, 25, 26]. Co-localization of
MDA-altered protein and apo B-containing lipoprotein, in
particular, suggests that LDL is main substrates for lipid
peroxidation and that Ox-LDL is formed in the diseased
glomeruli.
The frequency of intraglomerular Ox-LDL deposition in
this study is 6.6%, which is approximately one-fourth of
that of intraglomerular apo B deposition [11]. This suggests
that LDL trapped in the glomeruli of renal patients, in
general, might be refractory to oxidative modification. Or
Ox-LDL synthesized in vivo might be rapidly degraded or
removed [27]. The degree of oxidation determines the
degree of recognition of Ox-LDL by scavenger receptors
[28]. If less severely oxidized LDL is formed in the glomer-
uli, it might be taken up by monocytes/macrophages, lead-
ing to formation of foam cells. Even mesangial cells ex-
pressing scavenger receptors [29] could join this process.
The low frequency of intracellular Ox-LDL staining in the
mesangium suggests that MDA adducts are rapidly de-
graded within macrophages or mesangial cells, with de-
creased antibody reactivity. Or some Ox-LDL products,
which may not have common model epitope such as
MDA-modified peptide epitope, may not be recognized by
mAb OL-10, the only monoclonal antibody used in this
study. It is also possible that Ox-LDL formed in the
glomeruli might circulate in plasma unless the oxidation is
severe [27]. Thus, heavy accumulation of Ox-LDL in the
lesions of FSGS or subendothelial areas in this study might
reflect that LDL is so severely oxidized that no uptake
occurs by either the LDL or scavenger receptors.
Oxidative stress seems to be increased in uremic patients.
Plasma from uremic patients contains considerable levels
of lipid peroxidation products [30] and autoantibodies
against Ox-LDL [31]. Major modifications could occur in
Fig. 5. Electron micrograph of gold-labeled antibody to cytochrome b558,
mAb 449, in a glomerulus of a normal control (A) and a patient with
membranous nephropathy (B) showing the distribution of gold particles
in the cytoplasm of glomerular epithelial cells (GEC) and mesangial cells
(m). Abbreviations are: GBM, glomerular basement membrane; D, sub-
epithelial electron-dense deposits; CL, capillary lumen. (A) 333,000; (B)
346,000.
Fig. 6. Identification of malondialdehyde (MDA)-modified protein in
lysates of renal biopsy samples by immunoblotting. Samples (38 mg
protein/lane, lanes 1 to 3) and Cu11-catalyzed Ox-LDL (22 mg protein/
lane, lane 4) were separated on 5% polyacrylamide gel in SDS buffer
under reducing conditions and transferred onto nitrocellulose. Mouse
mAb OL-10 bound to a protein of approximate molecular weight ;260 kD
in samples of IgA nephropathy (lane 2) and FSGS (lane 3), whereas no
staining was seen in the normal control samples (lane 1). In Ox-LDL (lane
4), two proteins of approximate molecular weight ;240 kD and ;260 kD
were immunoreactive with mAb OL-10.
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the chemical properties of LDL from patients with uremia
and renal transplants, and these modifications would in-
crease susceptibility of LDL to oxidation [32, 33]. In this
study, most group 1 patients with heavy deposition of
Ox-LDL in the sclerotic segments had advanced glomeru-
losclerosis accompanied by renal dysfunction, partly sup-
porting this notion.
In PHN, a rat model of human membranous nephropa-
thy, ROS were produced by glomerular epithelial cells [18].
MDA adducts were localized to glomerular epithelial cells,
to the glomerular basement membrane and to immune
deposits [34]. Furthermore, apo B- and apo E-containing
lipoproteins accumulated within immune deposits of PHN
rats and were modified by lipid peroxidation [35]. We also
demonstrated immunogold particles for cytochrome b558
in glomerular epithelial cells of patients with membranous
nephropathy and of normal controls. However, the distri-
bution of MDA-protein epitopes in the periphery of glo-
merular capillary loops did not parallel the deposition of
apo B epitopes. This suggests that lipid peroxidation de-
composition products in the peripheral loops of human
glomeruli are not derived from LDL. The reason why a
positivity for MDA-adducts occurred in peripheral rims of
normal glomeruli is not clear. It is tempting to speculate
that in glomerular epithelial cells, which are not in direct
contact with circulation, antioxidant levels may be over-
whelmed by the generation of oxidants. Or lipid peroxida-
tion products, which could be present in urinary space, may
diffuse into glomerular epithelial cells to be sources of
MDA-adducts.
NADPH-oxidase complex is expressed not only in phago-
cytes but also in nonphagocytes, such as human mesangial
cells [17], human fibroblasts [36], murine osteoclasts [37],
and bovine vascular smooth muscle cells [38]. Unlike
phagocytes, the rate of superoxide production by cultured
human mesangial cells, endothelial cells and fibroblasts is
low and is not suicidal [17, 36]. Even in nonpurified blood
phagocytes, cytochrome b558 components are concentrated
in secretory vesicles for the formation of a rapidly mobiliz-
able pool [39]. In the present study, intracytoplasmic label-
ing for these components was rather randomly scattered in
the glomerular cells, and this supports the notion that
glomerular cells are much less likely than phagocytes to
generate ROS.
In view of the relatively limited superoxide-generating
potential of intrinsic glomerular cells, monocytes/macro-
phages might participate in lipid peroxidation of LDL in
this study. Whether Ox-LDL in the lesions of FSGS is the
cause or effect of glomerulosclerosis is unclear. We only
assume that intraglomerular foam cells having internalized
Ox-LDL could contribute to the eventual glomerulosclero-
sis, as originally proposed in atherogenesis [40]. In addi-
tion, peroxidative products of LDL stimulated collagen
gene expression in cultured human mesangial cells, suggest-
ing that Ox-LDL may be implicated in the development of
glomerulosclerosis [7].
In summary, the present study demonstrates that Ox-
LDL is present mainly in the lesions of glomerulosclerosis
and mesangial areas of patients with renal disease and that
intrinsic glomerular cells express cytochrome b558, the
potential of which may not suffice to be involved in
intraglomerular peroxidation of LDL.
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APPENDIX
Abbreviations used in this article are: apo B, apolipoprotein B; FSGS,
focal segmental glomerulosclerosis; HOCL, hypochlorite; LDL, low den-
sity lipoprotein; mAb, monoclonal antibody; MDA, malondialdehyde;
NADPH, reduced nicotinamide adenine dinucleotide phosphate; O2
2,
superoxide; Ox-LDL, oxidized low density lipoprotein; PBS, phosphate
buffered saline; PHN, passive Heymann nephritis; ROS, reactive oxygen
species; SDS, sodium dodecyl sulfate.
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